[
  {
    "ts": null,
    "headline": "Tracking George Soros's 13F Portfolio - Q3 2024 Update",
    "summary": "George Soros' 13F portfolio value rose from $5.57B to $6.92B in Q3 2024, with 177 positions. Learn more about the trades and holdings in Q3.",
    "url": "https://finnhub.io/api/news?id=23ba27c3f06964d870b41060251ca435b94957b9151d7d0c2a7648b1bb5d85ee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733774114,
      "headline": "Tracking George Soros's 13F Portfolio - Q3 2024 Update",
      "id": 131890146,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451506045/image_1451506045.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "George Soros' 13F portfolio value rose from $5.57B to $6.92B in Q3 2024, with 177 positions. Learn more about the trades and holdings in Q3.",
      "url": "https://finnhub.io/api/news?id=23ba27c3f06964d870b41060251ca435b94957b9151d7d0c2a7648b1bb5d85ee"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=f32c327e8ed0cf8cf376f8c97bca47dc53754b8962ad5104d6588495e61f23cd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762100,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 131933619,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=f32c327e8ed0cf8cf376f8c97bca47dc53754b8962ad5104d6588495e61f23cd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer",
    "summary": "On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival. Also Read: Merck’s Multi-Billion Dollar Drug Keytruda’s Investigational Under The Skin Injection At Par With Intravenous For",
    "url": "https://finnhub.io/api/news?id=363336615bb0bf94a5a5b87d0587d003c1c485a20e8f3425ed1d90e1eaa8d46f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733759451,
      "headline": "Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer",
      "id": 131871386,
      "image": "https://media.zenfs.com/en/Benzinga/6e5a819e4b51a0765cc7d446962862c1",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival. Also Read: Merck’s Multi-Billion Dollar Drug Keytruda’s Investigational Under The Skin Injection At Par With Intravenous For",
      "url": "https://finnhub.io/api/news?id=363336615bb0bf94a5a5b87d0587d003c1c485a20e8f3425ed1d90e1eaa8d46f"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level",
    "summary": "Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level",
    "url": "https://finnhub.io/api/news?id=70b703c474918210e78420e7ddfc5bae57a817b8de0261c806734077f0ff7c65",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733746893,
      "headline": "Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level",
      "id": 131873273,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Dow Jones Stocks: Apple Rallies To New Highs; Nvidia Sells Off To Key Support Level",
      "url": "https://finnhub.io/api/news?id=70b703c474918210e78420e7ddfc5bae57a817b8de0261c806734077f0ff7c65"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer",
    "summary": "RAHWAY, N.J., December 09, 2024--Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer",
    "url": "https://finnhub.io/api/news?id=0fede6d321d9d8d5a093bf93b3d8c124d571ab790629a0626c14d791dd3c659c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733744700,
      "headline": "Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer",
      "id": 131871387,
      "image": "https://media.zenfs.com/en/business-wire.com/f272383179f6e944ce37683c267abd9c",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 09, 2024--Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer",
      "url": "https://finnhub.io/api/news?id=0fede6d321d9d8d5a093bf93b3d8c124d571ab790629a0626c14d791dd3c659c"
    }
  },
  {
    "ts": null,
    "headline": "Merck: encouraging results in diffuse lymphoma",
    "summary": "Merck announces the results of a Phase II study evaluating zilovertamab vedotin, an investigational ADC , in combination with R-CHP to treat patients with untreated diffuse large B-cell lymphoma . In...",
    "url": "https://finnhub.io/api/news?id=8355f17444ddee8bb2db8e3e29f44db44bf9691d095252e4cc71b0b7d925e9ab",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733727856,
      "headline": "Merck: encouraging results in diffuse lymphoma",
      "id": 131867797,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces the results of a Phase II study evaluating zilovertamab vedotin, an investigational ADC , in combination with R-CHP to treat patients with untreated diffuse large B-cell lymphoma . In...",
      "url": "https://finnhub.io/api/news?id=8355f17444ddee8bb2db8e3e29f44db44bf9691d095252e4cc71b0b7d925e9ab"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now?",
    "summary": "We recently published a list of 11 Best Beginner Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best beginner stocks to invest in now. The Downsides to Stocks Rallying Higher Stocks in the United States are rallying high, […]",
    "url": "https://finnhub.io/api/news?id=322874e07137502ebff5b5273c370f98effc171e2cb3015722bc0945b432e57a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733725024,
      "headline": "Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now?",
      "id": 131871388,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 11 Best Beginner Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best beginner stocks to invest in now. The Downsides to Stocks Rallying Higher Stocks in the United States are rallying high, […]",
      "url": "https://finnhub.io/api/news?id=322874e07137502ebff5b5273c370f98effc171e2cb3015722bc0945b432e57a"
    }
  }
]